At the annual meeting of the American Diabetes Association meeting last week, a diabetes epidemiologist compares and contrasts competing CGMs both based on features and accuracy.
The world of data-driven diabetes care has been blown open in the last couple of years with advances in continuous glucose monitoring, digital health and, for Type 1 diabetics, the arrival of the "artificial pancreas."
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Continuous glucose monitoring has not been around a long time, but it appears that some who use it, swear by it.
In a long-awaited deal, Bayer has sold its diabetes unit to Panasonic for $1.13 billion, thanks to growing competition from next-gen diabetes monitors.